Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Stefan W. Krause, Hans‐Jochem Kolb et al.|Leukemia|2017Cited by 339
The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by ImatinibWiltrud Haaß, Wolfgang Seifarth|PLoS ONE|2012Cited by 17
Measurement of Separase Proteolytic Activity in Single Living Cells by a Fluorogenic Flow Cytometry AssayWiltrud Haaß, Wolfgang Seifarth|PLoS ONE|2015Cited by 12